Andrew E. Rawlins

Partner

Andrew E. Rawlins is a partner and transactional lawyer with over 30 years of experience in intellectual property, focusing his practice on technology-intensive matters. He is a member of the Health Care & Life Sciences Sector and the Automotive Industry Team.

Andrew structures and negotiates technology agreements to create business relationships between companies that leverage technology and create synergistic opportunities. Using his experience and focus on technology transactions, he works with clients to identify critical issues and efficiently complete deals. Throughout his career, he has assisted clients with other strategic intellectual-property issues, such as due diligence in commercial transactions, patent procurement and portfolio management, and opinions on validity and infringement.

His practice is informed by his prior experience as a patent examiner at the United States Patent and Trademark Office and having conducting patent litigation, including trials and arguments before various trial courts and the U.S. Court of Appeals for the Federal Circuit.

Andrew has particular experience in a variety of technology fields, including pharmaceuticals, biotechnology, medical devices, automotive, and consumer electronics.

Awards and Recognition

  • Recommended in the categories of patent licensing and transactional (2014 and 2015) and patent portfolio management and licensing (2016) by The Legal 500
  • Peer Review Rated in Martindale-Hubbell’s peer review rating system
  • Selected as a finalist for Washington Business Journal’s 2008 Top Washington Lawyers awards program
  • Advisory board member for BNA’s Medical Devices Law & Industry Report
  • Former member of the intellectual property advisory board for Law360

Affiliations

  • American Intellectual Property Law Association
  • American Bar Association
27 September 2023 Deals and Wins

Foley Represents Bioluminescence Ventures as Lead Investor in ReCode Therapeutics Series B Funding Extension

Foley & Lardner LLP represented Bioluminescence Ventures as the lead investor in the $50 million Series B funding extension for ReCode Therapeutics.
05 October 2022 Deals and Wins

Foley Represents Hanwha Impact Partners as Lead Investor in $121M Series C Funding for Cellarity

Foley & Lardner LLP recently represented Hanwha Impact Partners as a lead investor in the $121 million Series C funding round for Cellarity, a developer of cell behavior therapies.
14 September 2022 Deals and Wins

Foley Represents TCG Crossover as Lead Investor in EUR 49.2M Crossover Financing for Abivax

Foley & Lardner LLP recently represented TCG Crossover (TCGX) as the lead investor in the successful, oversubscribed EUR 49.2 million crossover financing for Abivax.
10 May 2022 Press Releases

Foley Represents BICO Group in Acquisition of Allegro 3D

27 April 2022 Press Releases

Foley Represents AltheaDx in Acquisition by Castle Biosciences

Foley & Lardner LLP announced today that it represented AltheaDx, Inc., a mental health diagnostics company, in its recent acquisition by Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care.
04 March 2022 Press Releases

Foley Represents Biotron Laboratories and Talus Mineral Company in Acquisition by Aceto

Foley & Lardner LLP announced today it served as legal advisor to Biotron Laboratories and Talus Mineral Company (collectively “Biotron”), two affiliated entities that in partnership manufacture and supply leading specialty minerals and nutritional ingredients, in its acquisition by Aceto, the supplier of choice for differentiated specialty materials in the life sciences and advanced technology end markets.